ODTX

Odyssey Therapeutics, Inc. - Common Stock (ODTX)

About Odyssey Therapeutics, Inc. - Common Stock (ODTX)

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

Details

Daily high
$21.95
Daily low
$20.51
Price at open
$20.65
52 Week High
$23.08
52 Week Low
$15.10
Market cap
1.0B
Dividend yield
-
Volume
188,754
Avg. volume
138,085
P/E ratio
--

Odyssey Therapeutics, Inc. - Common Stock News

Details

Daily high
$21.95
Daily low
$20.51
Price at open
$20.65
52 Week High
$23.08
52 Week Low
$15.10
Market cap
1.0B
Dividend yield
-
Volume
188,754
Avg. volume
138,085
P/E ratio
--